Bayer: presents data on prostate cancer

(CercleFinance.com) - Bayer will present new data from its prostate cancer portfolio at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancer Symposium, to be held in San Francisco, USA, February 13-15, 2025.


Data on darolutamide will include analysis of the phase III ARANOTE trial, evaluating the efficacy and safety of darolutamide and androgen deprivation therapy (ADT) in patients with hormone-sensitive metastatic prostate cancer (mHSPC) in terms of disease volume.

Analyses of the ARASENS Phase III trial will be presented. Results from the preliminary phase of the ARAMON Phase II trial, investigating darolutamide monotherapy in patients with castration-sensitive prostate cancer (cSPC) after biochemical recurrence (BCR), will also be presented.

An update on the ongoing ARASTEP Phase III trial evaluating darolutamide and ADT in patients with high-risk BCR prostate cancer will also be presented.

Darolutamide is already approved under the brand name Nubeqa TM in combination with ADT and docetaxel for the treatment of patients with mHSPC in over 80 markets, including the US, Japan, the EU and China.

Copyright (c) 2025 CercleFinance.com. All rights reserved.